Log in
Enquire now
‌

US Patent 11779632 IL-2 muteins and uses thereof

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11779632
Patent Inventor Names
Jyothsna Visweswaraiah
Joanne L. Viney
Kevin Lewis Otipoby
Erik Robert Sampson
Nathan Higginson-Scott
Date of Patent
October 10, 2023
Patent Application Number
17201350
Date Filed
March 15, 2021
Patent Citations
‌
US Patent 10294305 Method for treating a GD2 positive cancer
‌
US Patent 10358477 IL-15Ralpha sushi domain—IL-15 fusion proteins
‌
US Patent 10363273 Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
‌
US Patent 10363321 Nucleic acid products and methods of administration thereof
‌
US Patent 10376564 Interleukin-2 for treating food allergy
‌
US Patent 10428145 PD-1 binding proteins and methods of use thereof
‌
US Patent 10493148 PD-1 agonist antibodies and uses thereof
‌
US Patent 10676516 Targeted immunotolerance
...
Patent Primary Examiner
‌
Prema M Mertz
CPC Code
‌
A61K 38/2013
Patent abstract

The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11779632 IL-2 muteins and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.